Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in late antibody-mediated rejection after kidney transplant
2024-519095-66-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in humoral rejection and kidney allograft rejection comparing Felzartamab with Placebo (2 arms). Primary endpoint: Percentage of participants who achieve BPHR at Week 24. Planned start Jul 2025; status: authorised.
02
Drugs
felzartamab
03
Conditions
humoral rejectionkidney allograft rejection
Beyond the preview
Go deeper on 2024-519095-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519095-66-00.